ARCELLX INC (ACLX)
US03940C1009 - Common Stock
Overall ACLX gets a fundamental rating of 4 out of 10. We evaluated ACLX against 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ACLX as it has an excellent financial health rating, but there are worries on the profitability. ACLX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ACLX had negative earnings in the past year.
ACLX had a positive operating cash flow in the past year.
In the past 5 years ACLX always reported negative net income.
In the past 5 years ACLX reported 4 times negative operating cash flow.
1.2 Ratios
ACLX has a Return On Assets of -8.57%. This is amongst the best in the industry. ACLX outperforms 90.10% of its industry peers.
Looking at the Return On Equity, with a value of -14.56%, ACLX belongs to the top of the industry, outperforming 89.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.57% | ||
| ROE | -14.56% | ||
| ROIC | N/A |
ROA(3y)-39.71%
ROA(5y)-43.2%
ROE(3y)-54.89%
ROE(5y)-54.93%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ACLX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ACLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACLX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ACLX has been increased compared to 5 years ago.
The debt/assets ratio for ACLX has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.79 indicates that ACLX is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.79, ACLX is doing good in the industry, outperforming 79.18% of the companies in the same industry.
There is no outstanding debt for ACLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.21 | ||
| Altman-Z | 4.79 |
ROIC/WACCN/A
WACC9.22%
2.3 Liquidity
A Current Ratio of 6.06 indicates that ACLX has no problem at all paying its short term obligations.
ACLX has a better Current ratio (6.06) than 63.14% of its industry peers.
A Quick Ratio of 6.06 indicates that ACLX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.06, ACLX is in the better half of the industry, outperforming 63.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.06 | ||
| Quick Ratio | 6.06 |
3. Growth
3.1 Past
ACLX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.37%, which is quite impressive.
EPS 1Y (TTM)72.37%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q155.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to decrease by -13.46% on average over the next years. This is quite bad
Based on estimates for the next years, ACLX will show a very strong growth in Revenue. The Revenue will grow by 37.76% on average per year.
EPS Next Y-34.69%
EPS Next 2Y-17.99%
EPS Next 3Y-24.52%
EPS Next 5Y-13.46%
Revenue Next Year67.27%
Revenue Next 2Y38.93%
Revenue Next 3Y8.98%
Revenue Next 5Y37.76%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
ACLX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACLX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, ACLX is valued cheaply inside the industry as 97.95% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.58 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as ACLX's earnings are expected to decrease with -24.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.99%
EPS Next 3Y-24.52%
5. Dividend
5.1 Amount
No dividends for ACLX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARCELLX INC
NASDAQ:ACLX (4/30/2024, 10:19:43 AM)
50.92
-0.19 (-0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.71B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.57% | ||
| ROE | -14.56% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.06 | ||
| Quick Ratio | 6.06 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)72.37%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-34.69%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y